Associated Genetic Biomarkers
CCR5 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain CCR5 status as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Trials with CCR5 status in the inclusion eligibility criteria most commonly target breast carcinoma and malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CCR5 Expression .
Leronlimab and carboplatin are the most frequent therapies in trials with CCR5 as an inclusion criteria .
Significance of CCR5 in Diseases
Breast Carcinoma +
CCR5 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCR5 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Malignant Solid Tumor +
CCR5 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCR5 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.